IN.PACT AV DCB treats the cause — not just the symptoms of fistula stenosis — enabling you to get ahead of restenosis and go longer between interventions.1
By enabling dramatically fewer AV fistula interventions,1
the IN.PACT AV DCB can make a real impact ― clinically, financially,2
Hear from Dominick ―
a patient story.
Results from the IN.PACT™ AV Access Clinical Trial found in the IN.PACT™ AV drug-coated balloon (DCB) Instructions For Use (IFU).
*In an AV DCB study.
Medicare Costs Associated with Arteriovenous Fistulas Among US Hemodialysis Patients, Thamer et al., AJKD, March 2018 ; Patients who initiated HD with a catheter.
Target Lesion Primary Patency Rate based on KM estimates: Defined as freedom from clinically driven target lesion revascularization (CD-TLR) or access circuit thrombosis calculated at 180 days.
Access Circuit Primary Patency based on KM estimates: Defined as freedom from re-intervention in the access circuit or access circuit thrombosis calculated at 180 days.
Reduction in reinterventions: Defined as the number of interventions required to maintain target lesion primary patency calculated at 210 days.